IP Library Granted Patent US 9,308,295
Granted Patent B2
US 9,308,295 · App. 14/485,376 · Granted Apr 12, 2016

Oxygenated demineralized bone matrix for bone growth

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,308,295
App. No.
14/485,376
Granted
Apr 12, 2016
Kind
B2
Abstract

An improved composition for inducing bone growth is provided that is a mixture of DBM and a perfluorocarbon oxygen carrier. Injection/implantation of a composition of DBM and a perfluorocarbon results in enhancement of bone formation.

Claims (23)

1. A non-emulsified composition, consisting of:

demineralized bone matrix (DBM) powder, granules and/or fibers coated with a perfluorocarbon; and

optionally consisting of a handling agent selected from the group consisting of saline, glycerols, polyoxamers, lecithins, and combinations thereof.

2. The non-emulsified composition of claim 1 , wherein the perfluorocarbon has a boiling point at or within the range of about 50° C. to about 250° C.

3. The non-emulsified composition of claim 1 , wherein the perfluorocarbon has a boiling point at or within the range of about 140° C. to about 145° C.

4. The non-emulsified composition of claim 1 , wherein the perfluorocarbon is selected from the group consisting of perfluorodecalin, perfluorohexane, perfluoroperhydrophenanthrene, perfluorobutylamine (PFTBA), perfluorooctylbromide (PFOB), perfluoro-n-octane, octafluoropropane, perfluorodichlorooctane, perfluorodecane, perfluorotripropylamine, perfluorotrimethylcyclohexane, perfluoromethyladamantane, perfluorodimethyladamantane, perfluoromethyldecaline, perfluorofluorene, diphenyldimethylsiloxane, hydrogen-rich monohydroperfluorooctane, alumina-treated perfluorooctane, and mixtures thereof.

5. The non-emulsified composition of claim 1 , wherein the perfluorocarbon is perfluorodecalin, perfluorohexane, perfluorobutylamine, perfluoroperhydrophenanthrene, or mixtures thereof.

6. The non-emulsified composition of claim 1 , wherein the perfluorocarbon is perfluorodecalin.

7. The non-emulsified composition of claim 1 , wherein the perfluorocarbon is in an amount greater than 5% (w/w) based on the total weight of the perfluorocarbon and the DBM combined.

8. The non-emulsified composition of claim 1 , wherein the perfluorocarbon is in an amount from about 10 to about 70% by weight based on the total weight of the perfluorocarbon and the DBM combined.

9. The non-emulsified composition of claim 1 , wherein the perfluorocarbon is in an amount from about 32 to about 48% by weight based on the total weight of the perfluorocarbon and the DBM combined.

10. The non-emulsified composition of claim 1 used for enhancing bone growth.

11. The non-emulsified composition of claim 1 , wherein the DBM is in the form of powder and/or granules.

12. The non-emulsified composition of claim 11 , wherein the DBM is in the form of fibers.

13. A method of making a non-emulsified composition for bone growth, the method consisting of:

coating a perfluorocarbon on DBM powder, granules, and/or fibers to form a non-emulsified mixture; and

optionally adding a handling agent to the non-emulsified mixture, the handling agent being selected from the group consisting of saline, glycerols, polyoxamers, lecithins, and combinations thereof.

14. The method of claim 13 , wherein the perfluorocarbon has a boiling point at or within the range of about 50° C. to about 250° C.

15. The method of claim 13 , wherein the perfluorocarbon is selected from the group consisting of perfluorodecalin, perfluorohexane, perfluoroperhydrophenanthrene, perfluorobutylamine (PFTBA), perfluorooctylbromide (PFOB), perfluoro-n-octane, octafluoropropane, perfluorodichlorooctane, perfluorodecane, perfluorotripropylamine, perfluorotrimethylcyclohexane, perfluoromethyladamantane, perfluorodimethyladamantane, perfluoromethyldecaline, perfluorofluorene, diphenyldimethylsiloxane, hydrogen-rich monohydroperfluorooctane, alumina-treated perfluorooctane, and mixtures thereof.

16. The method of claim 13 , wherein the perfluorocarbon is perfluorodecalin.

17. The method of claim 13 , wherein the perfluorodecalin is in an amount greater than 5% (w/w) based on the total weight of the non-emulsified mixture.

18. The method of claim 13 , wherein the DBM is in the form of powder and/or granules.

19. The method of claim 13 , wherein the DBM is in the form of fibers.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2025
From: THERACELL, LLC
To: ARTERIOCYTE MEDICAL SYSTEMS, INC.
Reel/Frame 072388/0197 →
SECURITY INTEREST Recorded Sep 18, 2025
From: ISTO TECHNOLOGIES II, LLC; ADVANCED BIOLOGICS LLC,; ARTERIOCYTE MEDICAL SYSTEMS, INC.; THERACELL, LLC
To: GOLUB CAPITAL MARKETS LLC
Reel/Frame 072300/0216 →
RELEASE OF SECURITY INTEREST Recorded Sep 16, 2025
From: BARINGS FINANCE LLC, AS COLLATERAL AGENT
To: ARTERIOCYTE MEDICAL SYSTEMS, INC.; ISTO TECHNOLOGIES II, LLC; THERACELL, LLC; ADVANCED BIOLOGICS, LLC; BIOLOGICA TECHNOLOGIES, LLC
Reel/Frame 072274/0408 →
RELEASE OF SECURITY INTEREST Recorded Oct 18, 2023
From: TWIN BROOK CAPITAL PARTNERS, LLC
To: ISTO TECHNOLOGIES II, LLC
Reel/Frame 065269/0604 →
SECURITY INTEREST Recorded Oct 18, 2023
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.; ISTO TECHNOLOGIES II, LLC; THERACELL, LLC; ADVANCED BIOLOGICS, LLC; BIOLOGICA TECHNOLOGIES, LLC
To: BARINGS FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 065271/0059 →
CHANGE OF NAME Recorded Oct 11, 2023
From: THERACELL, INC.
To: THERACELL, LLC
Reel/Frame 065219/0102 →
SECURITY INTEREST Recorded Apr 4, 2022
From: THERACELL, INC.
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 059486/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2021
From: CARTER, ANDREW J.; SCARBOROUGH, NELSON L.; GRANT, RICHARD K.; PHILLIPS, FRANK M.; HOCHSCHULER, STEPHEN H.
To: THERACELL, INC.
Reel/Frame 057404/0774 →